Sandostatin

Acromegaly

Sandostatin is prescribed for patients with acromegaly, a condition where the body produces too much growth hormone, leading to the enlargement of hands, feet, and facial features. It is typically used when other treatments, such as surgery or radiation, have not been effective or are not an option. The medication works by lowering the levels of growth hormone and insulin-like growth factor-1 (IGF-1) in the blood.

Carcinoid Tumors

This medication is used to treat the symptoms of metastatic carcinoid tumors. These symptoms often include:

• Severe diarrhea
• Sudden reddening of the face and neck (flushing)

Vasoactive Intestinal Peptide Tumors (VIPomas)

Sandostatin is also used to treat profuse, watery diarrhea caused by VIPomas. These are rare tumors that produce a substance called vasoactive intestinal peptide, which affects how the body handles water and salts in the intestines.

How Sandostatin Works

Sandostatin belongs to a class of medications known as somatostatin analogs. It is designed to mimic the actions of somatostatin, a hormone that occurs naturally in the human body. This hormone acts as a chemical messenger that tells other parts of the body to stop or slow down the production of certain substances.

Regulating Growth Hormone

In conditions where the body produces excessive amounts of growth hormone, Sandostatin helps by binding to specific receptors. This action signals the body to reduce the release of growth hormone and insulin-like growth factor-1 (IGF-1), which helps manage symptoms related to abnormal tissue and bone growth.

Controlling Digestive Secretions

Sandostatin also regulates the digestive system by inhibiting the release of several gastrointestinal hormones and chemicals, such as serotonin and gastrin. By doing this, the medication helps to:

• Decrease the amount of fluid and salt secreted into the intestines.
• Slow the movement of the digestive tract.
• Reduce blood flow to the organs in the abdomen.
• Suppress the release of chemicals that cause symptoms like severe watery diarrhea and skin flushing.

Common Side Effects

Many people using Sandostatin experience mild to moderate side effects. These often include:

• Nausea, vomiting, or stomach pain
• Diarrhea, gas, bloating, or constipation
• Headache or dizziness
• Fatigue or tiredness
• Pain, redness, or stinging at the injection site

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Signs of gallbladder problems, such as severe pain in the upper right stomach area, fever, chills, or yellowing of the skin and eyes
• A very slow or irregular heartbeat
• Signs of thyroid problems, such as unexplained weight gain, feeling cold, or dry skin
• Significant changes in blood sugar, including symptoms of high blood sugar (increased thirst and urination) or low blood sugar (sweating, shakiness, or confusion)
• Severe or worsening constipation

Gallbladder and Pancreas Concerns

Sandostatin can inhibit gallbladder contraction and decrease bile secretion, which may lead to the formation of gallstones. Periodic ultrasound examinations of the gallbladder are often recommended during long-term therapy. In rare cases, inflammation of the pancreas (pancreatitis) has been reported.

Blood Sugar Regulation

This medication affects the release of insulin and glucagon, which can cause fluctuations in blood glucose levels. Both high blood sugar (hyperglycemia) and low blood sugar (hypoglycemia) may occur. Patients with diabetes may require adjustments to their insulin or oral glucose-lowering medications.

Heart and Thyroid Function

• Heart Rate: Slow heart rate (bradycardia) and other heart rhythm abnormalities have been observed. Caution is advised for patients with pre-existing heart conditions.
• Thyroid: Sandostatin can suppress the secretion of thyroid-stimulating hormone, potentially leading to hypothyroidism. Periodic thyroid function tests are usually necessary.

Nutritional and Organ Function

Long-term use may interfere with the absorption of dietary fats and vitamin B12. Additionally, patients with significant kidney or liver impairment may require dosage adjustments, as these conditions can affect how the body processes the drug.

Pregnancy

There are no adequate and well-controlled studies of Sandostatin use in pregnant women. Data from animal studies have not shown evidence of harm to the fetus at doses significantly higher than those used in humans. However, because animal studies are not always predictive of human response, Sandostatin should be used during pregnancy only if clearly needed.

Breastfeeding

It is not known whether Sandostatin passes into human breast milk. Because many drugs are excreted in human milk, healthcare providers typically recommend caution when administering this medication to someone who is breastfeeding. You should discuss the potential risks and benefits with your doctor.

Fertility and Contraception

In women with acromegaly, treatment with Sandostatin may normalize growth hormone and IGF-1 levels, which can lead to the restoration of fertility. Women of childbearing age should discuss the potential for pregnancy and the need for adequate contraception with their healthcare provider while using this medication.

Immediate-Release Injection

Sandostatin is available as a clear liquid solution for subcutaneous (under the skin) or intravenous (into a vein) administration. It is supplied in two formats:

• Single-dose ampules: These are designed for one-time use and are available in several concentrations.
• Multi-dose vials: These contain a preservative and allow for multiple doses to be drawn from a single vial.

Long-Acting Release (LAR) Depot

Sandostatin LAR Depot is a long-acting formulation administered by a healthcare professional as an injection into the gluteal muscle. It is provided as a kit that includes a vial of powder and a prefilled syringe of diluent, which are mixed together before administration.

The long-acting version is typically used for maintenance therapy once an effective and well-tolerated dose has been established with the immediate-release form.

FDA Approval Status

Sandostatin, which contains the active ingredient octreotide acetate, was initially approved by the U.S. Food and Drug Administration (FDA) in 1988. It is currently available as a brand-name product and in several generic versions.

Approved Indications

The FDA has approved Sandostatin for the treatment of the following conditions:

• Acromegaly: It is used to reduce blood levels of growth hormone and IGF-I in adults who have not responded adequately to other treatments like surgery or radiation.
• Carcinoid Tumors: It is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors, specifically to manage severe diarrhea and flushing.
• Vasoactive Intestinal Peptide-secreting Tumors (VIPomas): It is used to treat the profuse watery diarrhea associated with these tumors.

Safety and Regulatory Requirements

Sandostatin does not currently have any FDA boxed warnings or a Risk Evaluation and Mitigation Strategy (REMS) program. It is classified as a prescription-only medication. Regulatory status may vary between the immediate-release injection and the long-acting formulation (Sandostatin LAR Depot), though both are FDA-approved for specific indications related to hormone regulation.

Generic and Brand-Name Pricing

Sandostatin is available as a brand-name medication and as a generic version known as octreotide acetate. Generic medications are typically less expensive than brand-name drugs. While the immediate-release form of octreotide has several generic options, the long-acting formulation (Sandostatin LAR) may have different pricing and availability depending on the manufacturer.

Factors Affecting Cost

Several factors influence the total price of treatment with Sandostatin:

• Formulation: The immediate-release injection and the long-acting depot injection (LAR) have different price points.
• Dosage: The amount of medication required and the frequency of administration directly impact the overall cost.
• Insurance Coverage: Most private insurance plans and Medicare Part D cover octreotide, but they may require prior authorization or place the drug in a higher cost-sharing tier.
• Pharmacy Type: Because some versions of this medication require special handling or administration by a healthcare professional, they may be dispensed through specialty pharmacies, which can affect billing.

Financial Assistance Programs

Patients who are prescribed brand-name Sandostatin may be eligible for financial assistance. Manufacturers often provide co-pay cards or patient assistance programs to help reduce out-of-pocket expenses for eligible individuals, particularly those who are uninsured or underinsured.